Bovine pancreatic trypsin inhibitor (BPTI)/Aprotinin


  • Specification
  • Drug Information
  • Related Products
Cat#:  THP-0012
Product Name:  Bovine pancreatic trypsin inhibitor (BPTI)/Aprotinin
Description:  The bovine pancreatic trypsin inhibitor, BPTI is a protein with the main effect of slowing down of fibrinolysis.
Formula:  C284H432N84O79S7
Sequences:  RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
Species:  Bovine
CAS No. :  9087-70-1
Molecular Weight:  6511.439 Da
Storage:  Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Endotoxin Level:  <0.001 EU per 1 μg by the LAL method
Synonyms:  Aprotinin (bovine); Aprotinin Biosynthetic; Aprotinin Bovine; Aprotinin Concentrated Solution; Bovine Aprotinin; Bovine Pancreatic Trypsin Inhibitor; BPTI; Fibrinolysis Inhibitor; Trypsin Inhibitor, Pancreatic Basic
Drug name:  Aprotinin
Applications:  For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
Examples of Clinical Use:  Undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery
Pharmacodynamics :  The product is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. The product, through its inhibition of multiple mediators [e.g., kallikrein, plasmin] results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation. The product inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, the product reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b). The effects of the product use in CPB involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.
Mechanism of action:  Aprotinin inhibits several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml. Its action on kallikrein leads to the inhibition of the formation of factor XIIa. As a result, both the intrinsic pathway of coagulation and fibrinolysis are inhibited. Its action on plasmin independently slows fibrinolysis.
Affected organisms:  Humans and other mammals
Targets:  Target 1. Trypsin-1; Target 2. Chymotrypsinogen B; Target 3. Plasminogen; Target 4. Kallikrein-1
Catalog# Product Name Inquiry
THP-0010 Human tissue plasminogen activator, tPA, Alteplase Inquiry
THP-0011 Human tissue plasminogen activator, tPA, Anistreplase Inquiry
THP-0013 Recombinant C1 esterase inhibitor Inquiry
THP-0014 Direct inhibitor of human thrombin Inquiry
THP-0015 Human plasma kallikrein inhibitor Inquiry


For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Online Inquiry

  • Size: 100ug 500ug 1mg 5mg 10mg 100mg 500mg 1g
  • Conjugation: None R-PE APC Biotin FITC Alexa Flour Others
Search

USA

Enter your email here to subscribe.

Follow us on

Easy access to products and services you need from our library via powerful searching tools

Copyright © 2007 - 2021 Creative BioMart. All Rights Reserved.